Biomerica (Nasdaq:BMRA) is pleased to announce that its first generation food intolerance product has been shown to alleviate symptoms of Ulcerative Colitis and improve quality of life in an independent prospective study published in the Journal of Inflammatory Bowel Disease.

As quoted in the press release:

This study validates that Biomerica’s technology can assist in guiding the treatment regimen to alleviate symptoms and improve quality of life in patients with UC.  The study used the Company’s first-generation product with UC patients and found both significant symptom (Mayo Score) and Quality of Life improvement (QoL – a validated instrument used in FDA drug studies).  After intervention, the Mayo score was significantly lower in the intervention group than in the control group (2.41 ± 0.89 vs 3.52 ± 1.15, P < 0.05).  QoL also improved after guided food exclusion (P < 0.05).

UC patient samples were analyzed for the presence of antibodies specific to 14 different food antigens (egg, wheat, milk, corn, tomato, crab, rice, soybean, cod, shrimp, mushrooms, beef, chicken, and pork) using Biomerica’s enzyme-linked immunosorbent assay (ELISA).  The diet intervention was designed to last for 6 months and was managed by doctors, nurses, and nutritionists. Individual diets were guided based on the foods that tested positive in utilizing the Biomerica product. Colonoscopy examinations were performed within two weeks of study initiation and at the end of the diet intervention. The examinations were blinded to the groups.

Click here to read the full press release.